Vigil Neuroscience to be Acquired by Sanofi

Sanofi has entered into a definitive merger agreement to acquire Vigil Neuroscience (NASDAQ: VIGL) for up to $10.00 per share, representing a total equity value of approximately $600 million. The deal structure includes an $8.00 per share upfront payment and a $2.00 contingent value right (CVR) tied to VG-3927's first commercial sale. The acquisition focuses on Vigil's TREM2 agonist program, particularly VG-3927, a Phase 2-ready candidate for Alzheimer's disease treatment. The deal excludes Vigil's monoclonal antibody program Iluzanebart (VGL101), which will return to Amgen. The transaction, supported by shareholders holding approximately 16% of Vigil's shares, is expected to close in Q3 2025, subject to customary conditions including shareholder approval and regulatory clearances.

https://www.stocktitan.net/news/VIGL/vigil-neuroscience-enters-into-definitive-merger-agreement-to-be-14wfa9uhmoin.html